| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $260.2M | +53.2% |
| Cost of Revenue | $89.3M | +33.4% |
| Gross Profit | $170.9M | +66.2% |
| R&D Expense | $40.7M | +13.3% |
| SG&A Expense | $52.2M | +22.6% |
| Operating Income | -$12.0M | +72.6% |
| Pre-tax Income | -$12.8M | +72.9% |
| Income Tax | $0 | — |
| Net Income | -$12.8M |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $222.0M | +190.7% |
| Accounts Receivable | $34.6M | +47.7% |
| Inventory | $4.5M | +36.1% |
| Current Assets | $272.9M | +141.4% |
| Total Assets | $305.4M | +102.4% |
| Current Liabilities | $75.7M | +40.4% |
| Long-term Debt | $0 | -100.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $18.3M | +153.4% |
| Capital Expenditures | $1.3M | +121.8% |
| Investing Cash Flow | -$5.8M | -51.0% |
| Financing Cash Flow | $133.2M | — |
| Free Cash Flow | $16.9M | +148.7% |
| +72.9% |
| EPS (Basic) | -$0.35 | +94.3% |
| EPS (Diluted) | -$0.35 | +94.3% |
| Total Liabilities |
| $75.7M |
| -12.2% |
| Stockholders' Equity | $229.7M | +159.7% |